<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425564</url>
  </required_header>
  <id_info>
    <org_study_id>201516007.3</org_study_id>
    <nct_id>NCT04425564</nct_id>
  </id_info>
  <brief_title>Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>Clinico-pharmacological Study of Metronomic Capecitabine and Oxaliplatin Versus Classic XELOX in Egyptian Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer (CRC) in Egypt is advanced tumors at diagnosis. Although, the dramatic
      increase in efficacy, reduction of mortality, and improvements in survival by the use of
      standard doses of chemotherapy, some CRC patients suffer from severe toxicities besides
      disease progression. Use of chemotherapy less than the maximum tolerated dose, with no
      prolonged drug free breaks incapacitates the cells to engage in progression mechanisms,
      suggesting that it could be a better alternative to standard dose therapy with better
      toxicity profile
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II prospective study that included 70 (35 in each arm) metastatic
      Egyptian CRC cancer patients diagnosed at the National Cancer Institute, Cairo University
      between January 2016 and June 2018). Patients were randomly treated with either classic XELOX
      (arm A) or with capecitabine (2000 mg daily x 8 weeks) and oxaliplatin (30 mg/m2 weekly X 8
      weeks) then 2 weeks rest (arm B). Toxicities and the survival analysis after two years for
      both regimens were recorded. Blood samples are taken from both groups to assess
      pharmacokinetics of capecitabine and its relation to dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rates</measure>
    <time_frame>two years</time_frame>
    <description>Calculated with 95% confidence interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of toxicities and grades</measure>
    <time_frame>two years</time_frame>
    <description>Categorical data summarized by pecentages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak and trough levels of capecitabine and relation to dosing</measure>
    <time_frame>Two years</time_frame>
    <description>Numerical data summarized by means and standard deviation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>two years</time_frame>
    <description>Cox proportional hazard model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Two years</time_frame>
    <description>Kaplan and Meier test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Clinical Response</condition>
  <condition>Toxicity</condition>
  <condition>Survival</condition>
  <arm_group>
    <arm_group_label>Classic (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metronomic (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronomic XELOX</intervention_name>
    <arm_group_label>metronomic (B)</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Classic XELOX</intervention_name>
    <arm_group_label>Classic (A)</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples for pharmacological studies</intervention_name>
    <arm_group_label>Classic (A)</arm_group_label>
    <arm_group_label>metronomic (B)</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age 18-70 years of both sexes.

          -  PS 0-2 and histologically proven mCRC with unresectable metastases (rectal cancer is
             included to left side cancers).

          -  They should have measurable lesions (that can be accurately measured in at least one
             dimension using calipers or ruler and measurement must be at least 20 mm using
             conventional techniques or 10 mm using spiral CT scan).

          -  No previous treatment for metastatic disease and had ended adjuvant treatment &gt; 6
             months.

          -  peripheral neuritis less than grade 2.

          -  Normal organ functions:(Creatinine ≤1.2, Bilirubin ≤1.2, SGOT/SGPT&lt; 2N, HB &gt;9gm/dl,
             WBC&gt;3.5/dl with ANC &gt;1.5/dl, Plat ≥100/dl).

          -  For patients with liver metastases, Bilirubin should not be &gt;2.5N and transaminases
             not &gt;5N. (All patients were screened for HCV and HBS Ag by PCR).

          -  Adequate cardiac functions (EF&gt;55%)

        Exclusion Criteria:

          -  patients with only ascites or bone metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 6, 2020</last_update_submitted>
  <last_update_submitted_qc>June 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>metronomic capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

